Predicting Risk of Recurrence for Women With DCIS
Eileen Rakovitch, MD, associate professor, radiation oncologist, Sunnybrook Health Sciences Centre, Toronto, Ontario, discusses predicting risk of recurrence in women with DCIS.
Clinical Pearls
Eileen Rakovitch, MD, associate professor, radiation oncologist, Sunnybrook Health Sciences Centre, Toronto, Ontario, discusses predicting risk of recurrence in women with DCIS.
- Oncotype DX DCIS Score was validated as a predictor of risk of recurrence among women treated with breast-conserving surgery alone for DCIS.
- Women with a low-risk DCIS Score had a significantly lower risk of recurrence.
- Every 50 point increase in DCIS Score was associated with a two-fold increase in risk of recurrence.
<<<
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
